only
for
who have had
intolerant of hydroxyurea
1
Visit www.jakafi.com/HCP
illness and consider restarting or increasing the
dose of Jakafi. Instruct patients not to interrupt or
discontinue Jakafi without consulting their physician.
When discontinuing or interrupting Jakafi for reasons
other than thrombocytopenia or neutropenia, consider
gradual tapering rather than abrupt discontinuation
Non-melanoma skin cancers including basal cell,
squamous cell, and Merkel cell carcinoma have
occurred. Perform periodic skin examinations
The three most frequent non‐hematologic adverse
reactions (incidence >10%) were bruising, dizziness
and headache
A dose modification is recommended when
administering Jakafi with strong CYP3A4 inhibitors
or fluconazole or in patients with renal or hepatic
impairment. Patients should be closely monitored
and the dose titrated based on safety and efficacy
Use of Jakafi during pregnancy is not recommended
and should only be used if the potential benefit
justifies the potential risk to the fetus. Women taking
Jakafi should not breast‐feed
Please see Brief Summary of Full Prescribing Information
for Jakafi on the following page.
to see Full Prescribing Information and
learn more about Jakafi for use in PV
* A randomized, open-label, active-controlled
phase 3 trial comparing Jakafi with best available
therapy in 222 patients. Best available therapy
included hydroxyurea (60%), interferon/pegylated
interferon (12%), anagrelide (7%), pipobroman (2%),
lenalidomide/thalidomide (5%), and observation (15%).
The primary end point was the proportion of subjects
achieving a response at week 32, with response
defined as having achieved both Hct control (the
absence of phlebotomy eligibility beginning at the
week 8 visit and continuing through week 32) and
spleen volume reduction (a ≥35% reduction from
baseline in spleen volume at week 32). Phlebotomy
eligibility was defined as Hct >45% that is ≥3 percentage
points higher than baseline or Hct >48% (lower value).
Reference: 1. Jakafi Prescribing Information. Wilmington, DE: Incyte Corporation.